New betaclamycin and aclarubicin analogs obtained by prolonged microbial conversion with an aclarubicin-negative mutant
New betaclamycin and aclarubicin analogs obtained by prolonged microbial conversion with an aclarubicin-negative mutant
复制标题
DOI：
10.7164/antibiotics.49.669
复制
发表时间：
1996-07-01
影响因子：
3.3
通讯作者：
Yoshimoto, A
中科院分区：
文献类型：
--
作者：
Johdo, O;Yoshioka, T;Yoshimoto, A
利用阿克拉霉素阴性的伽利略链霉菌突变体对-红霉素酮和阿克拉霉素酮进行微生物转化，得到了新的蒽环类抗生素CG21-C和CG1-C，它们在每个添加的苷元的C-7处都含有红霉基-2-脱氧聚焦基-红胺基三糖残基。它们只有在长期的皈依文化发生时才会产生。由于通常的转化产物中含有肉桂酰-2-脱氧焦酰基-红胺酰残基，在进一步的培养过程中先积累后减少，很明显它们是由末端肉桂酰改性产生的。本文介绍了其分离纯化、结构鉴定、体外对培养L1210细胞的细胞毒性及形成机制。
Microbial conversion of beta-rhodomycinone and aklavinone using an aclarubicin-negative Streptomyces galilaeus mutant afforded new anthracycline antibiotics CG21-C and CG1-C which had a rednosyl-2-deoxyfucosyl-rhodosaminyl trisaccharide residue at C-7 of each added aglycone. They were produced only when a prolonged conversion culture took place. Because the usual conversion products containing a cinerulosyl-2-deoxyfucosyl-rhodosaminyl residue were at first accumulated and then decreased during further cultivation, it was evident that they occurred by the modification of terminal cinerulose. The isolation, purification, and structural determination are described, and cytotoxicity in vitro against cultured L1210 cells and the formation mechanism are discussed.